A Randomized, Double-blind Study of Treatment With a Known Anti-inflammatory (Prednisolone) to Evaluate Novel Endpoints in Patients With Chronic Obstructive Pulmonary Disease (COPD)
CompletadoFase 1ClinicalTrials.gov
ID: NCT00379730Tipo: INTERVENTIONALInicio: 21 de mar de 2006Fin estimado: 3 de may de 2007
Prednisolone will be used as a model medication to identify new clinical outcomes for future evaluation of new therapies in short-term studies (up to 4 weeks) in patients with Chronic Obstructive Pulmonary Disease (COPD).
Elegibilidad
Edad mínima: 40 YearsEdad máxima: 80 YearsSexo: ALL
Criterios de inclusión
An established clinical history of COPD
Evidence of bronchitis
Current or ex-smoker
Criterios de exclusión
COPD exacerbation requiring steroid and/or antibiotics in the last month
Taking oral or inhaled steroids for more than 14 days in the last 6 months
Unable to withhold salbutamol/albuterol for a 6 hour period
History of alcohol, substance or drug abuse within the last year.
Other significant medical condition e.g. diabetes
Cancer that has not been in complete remission for at least 5 years
As a result of the medical interview, physical examination or screening investigations, that the doctor considers the subject unfit for the study.
Intervenciones
drug
Prednisolone
Ubicaciones
GSK Investigational Site
Mendoza, Argentina
Patrocinadores
PrincipalGlaxoSmithKline
Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.
A Randomized, Double-blind Study of Treatment With a Know... | EligiMed